COGT

Cogent Biosciences, Inc.

7.20 USD
+0.20 (+2.86%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cogent Biosciences, Inc. stock is up 62.53% since 30 days ago. The next earnings date is May 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 6 March’s closed higher than February. In the last 8 Unusual Options Trades, there were 4 CALLs, 4 PUTs. 72% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
02 Jan 19:49 19 Jan, 2024 2.50 CALL 80 215
02 Jan 19:55 19 Jan, 2024 2.50 CALL 80 215
14 Feb 14:47 17 May, 2024 12.50 PUT 100 0
20 Feb 17:25 15 Mar, 2024 10.00 CALL 279 152
20 Feb 17:25 15 Mar, 2024 10.00 CALL 300 152
20 Feb 17:25 15 Mar, 2024 10.00 PUT 152 91
20 Feb 17:25 15 Mar, 2024 10.00 PUT 158 91
22 Feb 20:08 19 Apr, 2024 7.50 PUT 465 500

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. focuses on developing precision therapies for genetically defined diseases. Lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis.

  • JP Morgan
    Tue Feb 27, 12:58
    buy
    confirm
  • Citigroup
    Mon Feb 26, 11:44
    buy
    confirm
  • Baird
    Mon Feb 26, 05:42
    hold
    downgrade
  • Needham
    Mon Feb 26, 04:58
    buy
    confirm
  • Wedbush
    Fri Feb 23, 08:13
    hold
    confirm
  • Needham
    Mon Feb 12, 06:30
    buy
    confirm
  • Citigroup
    Thu Feb 8, 07:35
    buy
    initial